Phibro Animal Health (PAHC) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 52.17%. A quarter ago, it was expected that this maker of animal health products and nutritional supplements would post earnings of $0.34 per share when it actually produced earnings of $0.41, delivering a sur ...

Phibro Animal Health Corporation (PAHC) recently completed the acquisition of Zoetis Inc.’s (ZTS) medicated feed additive (MFA) product portfolio and certain water-soluble products. The latest acquisition comes with a lineup of products across cattle, swine and poultry, which will complement and expand Phibro’s species and product portfolios. This will help the company’s customers meet the highest standards of animal care, prevent diseases and enhance nutrition around the world. PAHC’s Likely Stock Trend Fo ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style S ...

Wall Street is sitting on its hands on Monday and Tuesday waiting for Alphabet, Microsoft, Apple, Amazon, and other mega-cap technology stocks to report their results in the final week of October.See the Zacks Earnings Calendar to stay ahead of market-making news. Amid the recent choppiness, some stocks are ripping to 52-week highs. Today we explore a screen that helps investors find soaring stocks trading near fresh highs that are also experiencing impressive upward earnings revisions activity, helping the ...

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Insulet (PODD) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision tren ...

Core Viewpoint - Phibro Animal Health (PAHC) is currently viewed as a more attractive investment option compared to Abbott (ABT) for value investors, based on various financial metrics and earnings outlook [1][7]. Valuation Metrics - PAHC has a forward P/E ratio of 14.73, significantly lower than ABT's forward P/E of 24.08, indicating that PAHC may be undervalued [5]. - The PEG ratio for PAHC is 1.70, while ABT's PEG ratio stands at 2.79, suggesting that PAHC offers better value relative to its expected earnings growth [5]. - PAHC's P/B ratio is 3.33 compared to ABT's P/B of 4.94, further supporting the notion that PAHC is a more favorable investment option [6]. Earnings Outlook - PAHC is experiencing an improving earnings outlook, which is a positive indicator in the Zacks Rank model, enhancing its attractiveness to investors [3][7].

It has been about a month since the last earnings report for Phibro Animal Health (PAHC) . Shares have added about 2.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Phibro due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Phibro Q4 Earnings and Revenues Beat, Oper ...

Core Insights - Phibro Animal Health (PAHC) and Abbott (ABT) are two stocks in the Medical - Products sector, with PAHC currently offering better value for investors compared to ABT [1][3]. Valuation Metrics - PAHC has a forward P/E ratio of 15.58, while ABT's forward P/E is significantly higher at 25.34 [5]. - The PEG ratio for PAHC is 1.80, indicating a more favorable valuation relative to its expected earnings growth compared to ABT's PEG ratio of 2.94 [5]. - PAHC's P/B ratio stands at 3.53, which is lower than ABT's P/B ratio of 5.20, suggesting that PAHC is more undervalued based on its book value [6]. Earnings Outlook - PAHC is experiencing an improving earnings outlook, which enhances its attractiveness in the Zacks Rank model, indicating a stronger potential for value investors [7].

Phibro Animal Health Corporation's (PAHC) sustained growth in the Animal Health business is backed by robust sales of vaccines and Medicated Feed Additives ("MFAs"). The company's focus on advancing vaccine technologies, along with the new vaccine production unit, instills optimism. Strong sales growth outside the United States seems encouraging. Yet, adverse macroeconomic impacts are a concern for Phibro's operations. In the past year, this Zacks Rank #2 (Buy) stock has rallied 71.5% compared with the indu ...

Core Viewpoint - Phibro Animal Health (PAHC) has a diversified product portfolio and strong presence in key growth areas, leading to a positive outlook for the stock, currently rated Zacks Rank 2 (Buy) [1] Factors Driving PAHC's Growth - Key products such as Medicated Feed Additives (MFAs) and nutritional specialty products enhance animal nutrition, with leading products like Stafac/V-Max/Eskalin approved in over 30 countries for poultry and swine [2] - Nutritional products like OmniGen-AF and Animate are increasingly utilized in the global dairy industry, while the company also manufactures vaccines for viral and bacterial diseases [2] - Phibro is focused on expanding its companion animal business and pipeline, which are significant growth areas for the company in the short and medium term [2] Recent Developments - In the fiscal fourth quarter, Phibro entered a purchase and sale agreement with Zoetis to acquire its MFA product portfolio and related assets, expected to complete in the initial phase of fiscal 2025 [3] Global Presence and Revenue Contribution - Phibro operates in over 80 countries, with a significant presence in high-growth regions such as Brazil, China, India, and Southeast Asia, allowing it to capitalize on global growth opportunities [4] - By the end of fiscal 2024, operations outside the U.S. contributed approximately 42.5% of total revenues, with forecasts indicating a 10% sales improvement in Latin America and Canada for fiscal 2026 [5] Stock Performance - The stock has increased by 63.4% over the past year, outperforming the industry average rise of 18.4%, driven by strategic expansion through innovation and acquisitions [6] Challenges Faced - The Mineral Nutrition business has encountered challenges due to adverse commodity price movements, resulting in flat growth year over year for fiscal 2024 [7] - Performance Products sales decreased by 10% year over year in fiscal 2024 due to reduced demand for personal care product ingredients and industrial chemicals, with projected declines of 4.9% and 6% in Nutritional Specialty and Performance Products for fiscal 2025, respectively [7]